Literature DB >> 31748349

Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.

A Robin Temming1, Steven W de Taeye1,2, Erik L de Graaf1, Louise A de Neef3, Gillian Dekkers2, Christine W Bruggeman4, Jana Koers2, Peter Ligthart5, Sietse Q Nagelkerke4,6, James C Zimring7, Taco W Kuijpers4,6, Manfred Wuhrer3, Theo Rispens2, Gestur Vidarsson8.   

Abstract

Ab-dependent cellular cytotoxicity (ADCC) is one of the most important effector mechanisms of tumor-targeting Abs in current immunotherapies. In ADCC and other Ab-dependent activation of myeloid effector cells, close cell-cell contact (between effector and target cell) and formation of immunological synapses are required. However, we still lack basic knowledge on the principal factors influencing ADCC potential by therapeutic Abs. In this study we investigated the combined roles of five factors affecting human NK cell-mediated ADCC, namely: 1) Ag density, 2) target cell membrane composition, 3) IgG FcγR polymorphism, 4) FcγR-blocking cytophilic Abs, and 5) Ab fucosylation. We demonstrate that the magnitude of NK cell-mediated ADCC responses is predominantly influenced by Ag density and Ab fucosylation. Afucosylation consistently induced efficient ADCC, even at very low Ag density, where fucosylated target Abs did not elicit ADCC. On the side of the effector cell, the FcγRIIIa-Val/Phe158 polymorphism influenced ADCC potency, with NK cells expressing the Val158 variant showing more potent ADCC. In addition, we identified the sialic acid content of the target cell membrane as an important inhibitory factor for ADCC. Furthermore, we found that the presence and glycosylation status of aspecific endogenous Abs bound to NK cell FcγRIIIa (cytophilic Abs) determine the blocking effect on ADCC. These five parameters affect the potency of Abs in vitro and should be further tested as predictors of in vivo capacity.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31748349     DOI: 10.4049/jimmunol.1900985

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.

Authors:  Nicholas A Maskalenko; Dmitry Zhigarev; Kerry S Campbell
Journal:  Nat Rev Drug Discov       Date:  2022-03-21       Impact factor: 112.288

2.  FcγR Binding and ADCC Activity of Human IgG Allotypes.

Authors:  Steven W de Taeye; Arthur E H Bentlage; Mirjam M Mebius; Joyce I Meesters; Suzanne Lissenberg-Thunnissen; David Falck; Thomas Sénard; Nima Salehi; Manfred Wuhrer; Janine Schuurman; Aran F Labrijn; Theo Rispens; Gestur Vidarsson
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

3.  Antibody mediated activation of natural killer cells in malaria exposed pregnant women.

Authors:  Timon Damelang; Elizabeth H Aitken; Wina Hasang; Ester Lopez; Martin Killian; Holger W Unger; Ali Salanti; Alexis Shub; Elizabeth McCarthy; Katherine Kedzierska; Martha Lappas; Stephen J Kent; Stephen J Rogerson; Amy W Chung
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 4.  Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases.

Authors:  Alex F Tang; Gospel Enyindah-Asonye; Catarina E Hioe
Journal:  Vaccines (Basel)       Date:  2021-02-02

5.  Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.

Authors:  Mads Delbo Larsen; Erik L de Graaf; Myrthe E Sonneveld; H Rosina Plomp; Jan Nouta; Willianne Hoepel; Hung-Jen Chen; Federica Linty; Remco Visser; Maximilian Brinkhaus; Tonći Šuštić; Steven W de Taeye; Arthur E H Bentlage; Suvi Toivonen; Carolien A M Koeleman; Susanna Sainio; Neeltje A Kootstra; Philip J M Brouwer; Chiara Elisabeth Geyer; Ninotska I L Derksen; Gertjan Wolbink; Menno de Winther; Rogier W Sanders; Marit J van Gils; Sanne de Bruin; Alexander P J Vlaar; Theo Rispens; Jeroen den Dunnen; Hans L Zaaijer; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Science       Date:  2020-12-23       Impact factor: 47.728

6.  C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro.

Authors:  A Robin Temming; Matthias Tammes Buirs; Arthur E H Bentlage; Louise W Treffers; Hannah Feringa; Steven W de Taeye; Taco W Kuijpers; Sietse Q Nagelkerke; Giso Brasser; Juk Yee Mok; Wim J E van Esch; Timo K van den Berg; Theo Rispens; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Front Immunol       Date:  2021-03-15       Impact factor: 7.561

7.  Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.

Authors:  Jan P Bogen; Stefania C Carrara; David Fiebig; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

8.  Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice.

Authors:  Rens Braster; Marijn Bögels; Hreinn Benonisson; Manfred Wuhrer; Rosina Plomp; Arthur E H Bentlage; Rianne Korthouwer; Remco Visser; J Sjef Verbeek; Marjolein van Egmond; Gestur Vidarsson
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 9.  Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity.

Authors:  Charles D Murin
Journal:  Front Immunol       Date:  2020-07-30       Impact factor: 7.561

10.  Generation of FX-/- and Gmds-/- CHOZN host cell lines for the production of afucosylated therapeutic antibodies.

Authors:  Weiyi Liu; Roshan Padmashali; Omar Quintero Monzon; Dianna Lundberg; Shan Jin; Brian Dwyer; Yun-Jung Lee; Anisha Korde; Sophia Park; Clark Pan; Bohong Zhang
Journal:  Biotechnol Prog       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.